# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 0 5 2007

In re Patent Application of

Avraham Cohen et al.

Application No.: 10/561,844

Filing Date: December 22, 2005

MONOHYDRATED SODIUM SALT OF Title:

S-TENATOPRAZOLE AND THE USE

THEREOF IN THERAPY

**Group Art Unit:** 

Examiner:

Confirmation No.: 5513

# **FIRST** INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

**Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

a

PTO-1	Enclosed is a FIRST Info	rmation Disclosure Statement ed patent application.	(IDS) and accompanying form			
$\boxtimes$	No additional fee for submission of an IDS is required.					
	The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.					
	A statement under 37 C.F.R. § 1.97(e) is also enclosed.					
	A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.					
	Charge	to Deposit Account No. 02-48	300 for the fee due.			
	A check in the amount of	is enclosed	for the fee due.			
	Charge	to credit card for the fee due.	Form PTO-2038 is attached.			
$\boxtimes$	The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.					
		Respectfully submitted,				

**BUCHANAN INGERSOLL & ROONEY PC** 

Date February 5, 2007

Registration No. 45774

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Avraham Cohen et al.

Application No.: 10/561,844

FEB 0 5 2007

Examiner:

Confirmation No.: 5513

For: MONOHYDRATED SODIUM SALT OF S-TENATOPRAZOLE AND THE USE THEREOF IN THERAPY

Confirmation No.: 5513

### FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

A copy of the International Search Report mailed 30 November 2005 from the corresponding PCT application is enclosed.

FIRST Information Disclosure Statement Application No. 10/561,844 Attorney's Docket No. 1032013-000133 Page 2

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. § 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No.02-4800. This paper is submitted in duplicate.

Respectfully submitted,

**BUCHANAN INGERSOLL & ROONEY PC** 

Date: February 5, 2007

By:

Melissa M. Hayworth

Registration No. 45774

P.O. Box 1404 Alexandria, VA 22313-1404 703 836 6620

#### Substitute for form 1449A/PTO & 1449B/PTO Complete if Known **Application Number FIRST** 10/561,844 O/561,0-1. December 22, 2005 Avraham COHEN et a FEB 0 5 2007 **INFORMATION DISCLOSURE** Filing Date STATEMENT BY APPLICANT **First Named Inventor Examiner Name** (use as many sheets as necessary) Sheet of 1 **Attorney Docket Number** 1032013-000133

U.S. PATENT DOCUMENTS					
Examiner Document Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)	
			•		

FOREIGN PATENT DOCUMENTS											
				STATUS							
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	2 848 555		France	06-18-2004				X			
	2004/074285		PCT	09-02-2004				X			
	0 254 588		Europe	01-27-1988				Х			
	<del></del>										
						<u> </u>			<u>.</u>	<u></u>	

NON-PATENT LITERATURE DOCUMENTS					
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journa serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Bunpei Kakinoki et al. "General Pharmacological Properties of the New Proton Pump Inhibitor (+)-5-Methoxy-2-[[(4-methoxy-3, 5-dimethylpyrid-2-yl)methyl]sulfinyl]-1H-imidazo[4,5-b]pyridine", Vol. 21, No. 3, 1999, pgs. 179-187.				
	International Search Reported dated 30 November 2005				

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.